FDA OKs Keytruda in Early Bladder Cancer

]]>(MedPage Today) -- WASHINGTON--The FDA approved pembrolizumab (Keytruda) on Wednesday as a bladder-sparing option for certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC) who are ineligible for radical cystectomy or who...